Merck & Co., Inc. (6MK.F)
| Previous close | 122.20 |
| Open | 121.40 |
| Bid | 121.00 x 100000 |
| Ask | 121.00 x 100000 |
| Day's range | 120.80 - 121.40 |
| 52-week range | 90.70 - 123.20 |
| Volume | |
| Avg. volume | 343 |
| Market cap | 307.003B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 144.29 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.84 (2.35%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Insider Monkey
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.07, expectations were $1.94. Merck & Co., Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […]
- Simply Wall St.
Merck & Co., Inc. (NYSE:MRK) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Merck & Co., Inc. ( NYSE:MRK ) just released its quarterly report and things are looking bullish. The company beat...
- Benzinga
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me
